

OIE Reference Laboratory Reports Activities

Activities in 2021

This report has been submitted : 2022-01-24 10:58:56

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Glanders
Address of laboratory:	14 rue Pierre et Marie Curie 94701 Maisons-Alfort Cedex, FRANCE
Tel.:	+33 (0)-1 49.77.13.0
Fax:	+33 (0)-1 49.77.13.4
E-mail address:	karine.laroucau@anses.fr
Website:	
Name (including Title) of Head of Laboratory (Responsible Official):	Dr Pascal Boireau
Name (including Title and Position) of OIE Reference Expert:	Dr Karine Laroucau
Which of the following defines your laboratory? Check all that apply:	Governmental

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
CFT	yes	55	138
ELISA	yes	19	74
Direct diagnostic tests			
PCR	yes	0	53
Bacteriology	yes	0	53

**ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.**

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

No

4. Did your laboratory produce vaccines?

Yes

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

Name of OIE Member Country seeking assistance	Date (month)	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
NEPAL	april	0	10

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

No

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	OIE Member Countries involved other than your country
Genotyping of <i>B. mallei</i> strains (Brazil)	2 years	Characterisation of the strains	UPFE	BRAZIL
Genotyping of <i>B. mallei</i> strains (India)	1 year	Characterisation of the strains	ICRAD	INDIA
Establishment of a standard serum	1 year	To have a standard serum for CFT and ELISA harmonisation	University of Faisalabad FLI CVRL ICRAD	

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:
Investigation in Nepal, description of a first case

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:
paper submitted

13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 4

Wang G, Glaser L, Scott NE, Mohamed YF, Ingram R, Laroucau, Valvano MA. A glycoengineered antigen exploiting a conserved protein O-glycosylation pathway in the Burkholderia genus for diagnosis of glanders infections. Virulence 12(1):493-506.

Hébert L, Polledo G, Lecouturier F, Giorgi M, MadelineA, Beck C, Laroucau K, Büscher P, Hans A, Becù T. Serological evidence of the circulation of equine infectious anemia, West Nile fever, surra and equine piroplasmiasis in a herd of semi-wild horses in northern Argentina. Vet Parasitol: Reg Stud Reports. 24:100566.

Singha H, Vorimore F, Saini S, Deshayes T, Saqib M, Tripathi BN, Laroucau K. Molecular epidemiology of Burkholderia mallei isolates from India (2015-2016): New SNP markers for strain tracing. Infect Genet Evol.

95:105059

EFSA Panel on Animal Health and Welfare (AHAW), Saxmose Nielsen S, Alvarez J, Bicout DJ, Calistri P, Canali E, Drewe JA, Garin-Bastuji B, Gonzales Rojas JL, Gortázar Schmidt C, Herskin M, Michel V, Miranda Chueca MA, Padalino B, Pasquali P, Spoolder H, Ståhl K, Velarde A, Viltrop A, Winckler C, Gubbins S, Laroucau K, Eleni Antoniou S, Aznar I, Broglia A, Lima E, Van der Stede Y, Zancanaro G, Clare Roberts H. Assessment of the control measures of the category A diseases of Animal Health Law: Burkholderia mallei (Glanders). EFSA Journal 2022;20(1):7069www.efsa.europa.eu/efsajournal. <https://doi.org/10.2903/j.efsa.2022.7069>

Wang G, Glaser L, Scott NE, Mohamed YF, Ingram R, Laroucau, Valvano MA. A glycoengineered antigen exploiting a conserved protein O-glycosylation pathway in the Burkholderia genus for diagnosis of glanders infections. Virulence 12(1):493-506.

Hébert L, Polledo G, Lecouturier F, Giorgi M, MadelineA, Beck C, Laroucau K, Büscher P, Hans A, Becù T. Serological evidence of the circulation of equine infectious anemia, West Nile fever, surra and equine piroplasmiasis in a herd of semi-wild horses in northern Argentina. Vet Parasitol: Reg Stud Reports. 24:100566. Singha H, Vorimore F, Saini S, Deshayes T, Saqib M, Tripathi BN, Laroucau K. Molecular epidemiology of Burkholderia mallei isolates from India (2015-2016): New SNP markers for strain tracing. Infect Genet Evol. 95:105059

b) International conferences: 0

c) National conferences: 0

d) Other:

(Provide website address or link to appropriate information) 0

**ToR 7: To provide scientific and technical training for personnel from OIE Member Countries
To recommend the prescribed and alternative tests or vaccines as OIE Standards**

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

No

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO17025	Attestation 1-2246 révision 20.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
CFT	COFRAC
ELISA	COFRAC

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

(See *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4*)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Yes

Purpose of the proficiency tests: ¹	Role of your Reference Laboratory (organiser/ participant)	No. participants	Participating OIE Ref. Labs/ organising OIE Ref. Lab.
Proficiency test - CFT	Organiser	27	OIE ref Lab in lina (Germany, Dr M. Elschner) OIE ref Lab in Dubai (Germany / Dr Wernery)
Proficiency test - PCR	Organiser	15	OIE ref Lab in lina (Germany, Dr M. Elschner)

¹ validation of a diagnostic protocol: specify the test; quality control of vaccines: specify the vaccine type, etc.

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant OIE Reference Laboratories
Constitution of a reference serum for serology	To have a reference serum for CFT/ELISA standardisation	OIE ref Lab in lina (Germany, Dr M. Elschner) OIE ref Lab in Dubai (Germany / Dr Wernery)

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

Purpose for inter-laboratory test comparisons ¹	No. participating laboratories	Region(s) of participating OIE Member Countries
CFT	27	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input checked="" type="checkbox"/> Middle East
PCR	15	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

No

25. Additional comments regarding your report: